Want to see GRCE full AI Analyst Report?
GRCE Stock Chart & Stats
$2.20
-$0.02(-0.85%)
At close: 4:00 PM EDT
$2.20
-$0.02(-0.85%)
Day’s Range― - ―
52-Week Range$1.79 - $5.18
Previous CloseN/A
Volume127.09K
Average Volume (3M)127.16K
Market Cap
$45.23M
Enterprise Value$25.45
Total Cash (Recent Filing)$13.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 16, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding21,035,930
10 Day Avg. Volume97,210
30 Day Avg. Volume127,159
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageAn effectively debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater financial flexibility than a highly leveraged development biotech, although operating losses still require careful capital management.
Extended Cash RunwayFunding visibility through the end of 2028 gives management time to execute manufacturing and regulatory work for GTx-104 without facing an immediate financing deadline. That runway can support a more deliberate development plan and reduce near-term liquidity pressure.
Regulatory PathwayThe absence of requested additional clinical studies keeps the remaining GTx-104 work concentrated on manufacturing compliance and non-clinical requirements. A dual-source strategy may improve execution resilience and preserve a clearer path toward NDA resubmission.
Bears Say
No Revenue BaseWith no reported revenue, GRCE has not yet demonstrated commercial demand or an operating engine capable of funding its activities. The business therefore remains dependent on successful product development and eventual commercialization before recurring revenue can emerge.
Persistent LossesPersistent operating and net losses show that the current business is not self-sustaining and that profitability has not stabilized. Continued losses can erode the equity base over time, increasing dependence on financing and making future execution more sensitive to capital availability.
Negative Cash GenerationConsistently negative operating and free cash flow means GRCE must use external capital to fund research, regulatory activity, and corporate operations. Even with burn improving from some prior periods, the lack of self-funding remains a durable constraint on strategic flexibility.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.79 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $45.23M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 45 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.781.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 21,035,930 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -1.429%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (81.82% Upside)
$4.00 (81.82% Upside)
Blogger Sentiment
Bullish
GRCE Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $318.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
$4.00
▲(81.82% Upside)
Technical Analysis
Ownership Overview
20.12% Insiders
1.94% Mutual Funds
7.30% Other Institutional Investors
68.59% Public Companies and
Individual Investors